Compare Huntington Bancshares Incorporated (HBAN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Mesoblast Limited — how do they compare? Huntington Bancshares Incorporated trades at $15.32 (market cap $31.04B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Huntington Bancshares Incorporated is far larger — about 17.7× Mesoblast Limited's market cap, and Huntington Bancshares Incorporated pays a 4.04% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Mesoblast Limited for 15 Days on average.
| HBAN | MESO | |
|---|---|---|
Market Cap | $31.04B | $1.75B |
Volume | 23,864,172 | 239,027 |
Sector | Financials | Health |
52-Week High | $19.27 | $20.96 |
52-Week Low | $15.02 | $13.19 |
Typical Hold Time | 52 Days | 15 Days |
Enterprise Value | $49.57B | $1.83B |
Dividend Yield | 4.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.37, up 1.32% today, but faces a bearish technical outlook with support at $15 and resistance at $16. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026, with Q3 2026 results pending. Revenue grew to $8.13B in 2025, and the stock trades at a P/E of 11.82, below the industry average, while analyst sentiment is split with a consensus price target of $19.60.
HBAN offers value with solid profitability and shareholder returns via dividends and buybacks, but near-term headwinds include interest rate pressures, margin compression, and lowered 2027 guidance. Risks involve economic sensitivity and competitive lending markets, yet institutional interest remains with significant holdings. The stock presents a cautious opportunity for value investors amid volatility.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
